Skip to Content

Insights From Our Labs to Yours

Covance Blog

  • Home
  • Industry
    • Device
    • Drug
    • Chemical
    • Crop
  • Phase
    • Discovery
    • Preclinical/Nonclinical
    • Phase I-IIa
    • Phase IIb-III
    • Pilot
    • Pivotal
    • Formulation, Packaging, etc.
  • Molecule Type
    • Biologics
    • Small Molecules
    • Biosimilars
    • Biomarkers
    • Cell/Gene Therapies
  • Data/Informatics
    • SEND
    • Modeling
    • Patient Recruitment
    • Xcellerate
  • About Us
    • Careers and Culture
    • Contact Us
    • Covance.com

Alicia M. Baker

Alicia M. Baker, Director, Global Regulatory Affairs Strategy, Covance

Home / Alicia M. Baker
Rheumatoid Arthritis Biosimilars
Share

Rheumatoid Arthritis Biosimilars: Regulatory and Clinical Considerations

by Alicia M. Bakerupdated on Monday, February 17, 2020Tuesday, June 6, 2017

Three biosimilars for rheumatoid arthritis (RA) were approved by the FDA last year, but the regulatory pathway in the U.S. is still considered a new frontier, especially when compared to regulatory guidance in the EU. With our global industry’s growing interest in developing biosimilars, it’s critical that sponsors have a …

Copyright © 2020 Covance Inc. All rights reserved.